Table 1 Patient demographics and baseline characteristics, safety set

Age, mean ± SD, years

61.3 ± 9.3

Female, n (%)

43 (48)

Duration of PD, mean ± SD, years

7.4 ± 3.9

Race, n (%)

 Asian

84 (93)

 Caucasian

6 (7)

Hoehn and Yahr Stage during “on”, n (%)

 1

1 (1)

 2

65 (72)

 3

23 (26)

 4

1 (1)

Hoehn and Yahr Stage during “off”, n (%)^†

 2

35 (39)

 3

46 (51)

 4

7 (8)

Levodopa dosage, mean ± SD, mg/day

547.2 ± 287.7

Oral dopamine receptor agonists dosage, mean ± SD, mg/day

 Pramipexole

0.9 ± 0.5 (n = 51; 57%)

 Ropinirole

3.4 ± 2.0 (n = 39; 43%)

Oral dopamine receptor agonist formulation, n (%)

 IR

54 (60)

 ER

36 (40)